Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) reported that results from the firm’s Cancer HTS research shows that specific ratios of Cannabinoids directed Apoptosis in ‘MDA-MB-231’ breast cancer cell viability. The company is presently advancing a personalized treatment dependent upon screening of subjects’ biopsy and offering specified cannabinoid drug which comprises anti-tumor properties. It is considered this technology will allow oncologist and other treating physicians to offer cancer patients with a modified anti-cancer cannabinoid based treatment.
The management speaks
Itamar Borochov, the CEO of Cannabics Pharmaceuticals, said that they are establishing a data base of compounds and patients, the clinical efficacy and the screening data will be centralized and in patented software. Data from the screening of different cancer types will result in new patent applications and new data of compounds having anti-cancer properties.
With the demand for legalized cannabis and marijuana infused products quickly growing, industry operators are looking for capital funding prospects to quickly advance new technology, products, buy considerable resources and assets to maximize businesses, including crop growth. Cannabis operators in the industry this week comprise MassRoots, Inc. (OTCQB: MSRT), Marapharm Ventures Inc. (OTCQB: MRPHF), Cannabics Pharmaceuticals, Terra Tech Corp. (OTCQX: TRTC) and GW Pharmaceuticals plc (NASDAQ: GWPH).
Marapharm reported that it is compensating the Nevada Title, Escrow Agent, for comprehensive payment and discharge of its initial mortgage financing on 5.9 acres based in Apex Industrial Park. In addition, it would be compensating cash without debt for the formerly reported addition of 1.1 connecting acres.
Cannabics Pharmaceuticals, a U.S based public firm, is committed to the advancement of Personalized Palliative and Anti-Cancer treatments. The firm’s R&D facility is based in Israel, where it is approved by the Ministry of Health for its activities in both academic and scientific research as well as existing clinical trials underway at Rambam Hospital. Its scientific focus is on recognizing and using the therapeutic properties of certain natural Cannabinoids. Cannabics’ objective is to create personalized therapies for cancer patients, using personalized bioinformatics tools and advanced screening systems.
